Day Two
**This event has run**
Take a look at what topics and speakers were part of the 4th Longevity Therapeutics Summit.
8:00 am
Morning Coffee
8:50 am
Chair’s Opening Remarks
Smart Investments: How to Invest in Longevity
9:00 am Human Aging & Longevity: The Immune System Takes the Lead
Synopsis
*Virtual Talk
- Examining how over the past decade it has become apparent that the immune system determines, at large, the rate of aging
- Discussing how using multi-omic approaches, AI/ML, and systems biology methods in large cohorts, it is now possible to derive biomarkers and mechanisms of immune-mediated aging rates
- Integrative analysis of these multiple layers of biological information can yield efficacious and safe longevity interventions
9:30 am A Broad Overview of the Aging/Longevity Investment & Startup Landscape
Synopsis
- Analyzing breakdowns of the startups in the field
- Considering overall trends in the space as a whole
- What’s missing when viewing the whole field as a pipeline?
10:00 am Longevity-Derived Financial Instruments as Practical Implementation of Longevity Biomarkers
Synopsis
- Explaining that biomarkers of human longevity possess valuable and precise information about the life expectancy of a given person or cohort. This implies that biomarkers-based methods have a significant impact on longevity risks mitigation
- Discussing the variety of financial instruments that are highly exposed to longevity risks:
– Equity reverse mortgage, allowing enhanced longevity risks optimization for both the customer and the provider
– Loan management for retirees
– In longevity annuity contracts-providing feasible means for risk hedging
– Longevity-tied derivatives can benefit from the implementation of the biomarkers-based longevity indices
10:30 am Focusing on Investments in AI/Deep Tech & Biotech/Longevity
Synopsis
Navigating the investment landscape in longevity with respect to artifical intelligence, deep tech and machine learning
11:00 am Panel Discussion: Investing in Longevity
Synopsis
Join leaders from venture capital, large pharmaceuticals and innovative biotechs as they discuss how to navigate investments and funding in this lucrative field
- Outlining the current longevity/aging investment and startup landscape
- Discussing the investment potentialin this lucrative field
- Analyzing areas that could be improved upon in this field
11:30 am
Morning Networking Break
Evaluating the Progress in Longevity Therapeutics Targeting Mitochondrial Dysfunction & Metabolic Diseases
12:00 pm Get Your Signals Straight: Extending Healthspan with NaNots Against Pathogenic Signals & Inhibitors
Synopsis
- The Signalome & role in disease & aging
- What are NaNots?
- Targeting soluble immune inhibitors as senolytics (FDA disease is cancer – targets are the same)
- Targeting inflammatory cytokines to treat “Inflamm-aging” (FDA disease is sepsis – targets are the same)
- Ultimate vision of NaNots as “signal tweakers” for maintaining health
12:30 pm Discussing Mitophagy Activation Via the Natural Postbiotic Urolithin A to Boost Mitochondrial Health During Aging
Synopsis
*Virtual Speaker
- Outling mitophagy activation as a key anti-aging strategy to boost mitochondrial health
- Exploring the discovery of the gut microbiome postbiotic Urolithin A to activate mitophagy
- Analyzing clinical evidence from different RCTs showing the potential of Urolithin A to improve mitochondrial health during aging
1:00 pm Exploring the Heavy Handling of Age-Related Diseases Using Lipid Peroxidation
Synopsis
- Examining evidence that suggests that lipid peroxidation is an overlooked common denominator of various age-related pathologies
- Analyzing the reasons why antioxidants are inefficient
- Understanding the isotope reinforcement of changes essential lipids chemically, without changing them chemically
1:30 pm
Lunch Break
Synopsis
Take this opportunity to meet our expert speakers, connect with your peers and explore solutions and products in our exhibition booths
2:15 pm Highlighting the Mitochondrial Micro-Proteome as a Platform for Healthspan-Related Drug Discovery
Synopsis
- Discussing how the mtDNA contains hundreds of previously unrecognized small open-reading frames that encode a novel class of mitochondrial-derived peptides (MDPs)
- Exploring several new and innovative bioinformatic approaches that allow the discovery of disease relevant MDPs that can serve as targets for diseases of aging
- Evaluating specific MDPs that are mutated in conditions such as diabetes and Alzheimer’s disease represent novel precision-aging treatment strategies
Implementing Artificial Intelligence & Machine Learning in Longevity Therapeutics
2:45 pm Discussing the Use of Sarconeos (BIO101) for the Treatment of an Emerging Age-Related Disease, Covid-19
Synopsis
- Outlining Covid-19 as an age-related disease
- SARS-Cov-2, the Renin Angiotensin System and Severe Acute Respiratory Syndrome
- Sarconeos (BIO101), a MAS activator for the treatment of Covid-19 in elderlies
3:15 pm Treating Alzheimer’s Disease by Draining Detritus from the Brain
Synopsis
- Using artificial intelligence to show that aging reduces the brain’s clearance of metabolites
- Explaining the effects of an implantable device which restores the clearance mechanism
- Reviewing preparation for clinical trials of the Arethusta device which begins in 2023
3:45 pm
Afternoon Coffee Break
4:15 pm Using Artificial Intelligence in Drug Discovery & Development for Diseases of Aging: Opportunities & Considerations
Synopsis
- Building classification models for diseases of aging
- Evaluating the use of AI for unbiased drug screening
- Discussing the potential of AI in drug development for aging diseases beyond discovery
Progressing Towards the Clinic
4:45 pm Reversing Cell Aging in Human Trials: The CNS, Cardiovascular System, & Other Tissues
Synopsis
- Aging: What it is and what are we missing?
- Exploring cell aging in molecular detail and its clinical implications
- Discussing the optimal point of intervention clinically and financially
5:15 pm Discussing the Emerging Field of Using an RNA Therapeutic for Age- Related Disorders
Synopsis
- Highlighting the rapidly emerging field of mRNA therapeutics and exploring why it will have a transformative effect on clinical care, including age-related diseases
- Analyzing why vascular aging is the underlying cause of most morbidity and mortality, including heart attack and stroke, as well as dementia and other agerelated disease
- Examining proof-of-concept studies in iPSC-derived vascular cells and murine models of aging, using a novel mRNA therapeutic
5:45 pm
Chair’s Closing Remarks
Download the Event Guide for full session details!
